<?xml version="1.0" encoding="UTF-8"?>
<ref id="B48-molecules-25-03846">
 <label>48.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Li</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Zheng</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Yi</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Kong</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Gong</surname>
    <given-names>M.</given-names>
   </name>
  </person-group>
  <article-title>Myricetin: A potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist</article-title>
  <source>FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.</source>
  <year>2017</year>
  <volume>31</volume>
  <fpage>2603</fpage>
  <lpage>2611</lpage>
  <pub-id pub-id-type="doi">10.1096/fj.201601339R</pub-id>
  <?supplied-pmid 28270518?>
  <pub-id pub-id-type="pmid">28270518</pub-id>
 </element-citation>
</ref>
